Galecto is a Danish drug development company based in Copenhagen. Galecto focuses on small molecule therapeutics directed at biological targets involved in development of fibrotic diseases. The lead program GB0139 is indicated for the treatment of idiopathic pulmonary fibrosis and is currently in phase 2b clinical testing.
YEAR OF INVESTMENT
2020
SECTOR
Drug development
LOCATION
Copenhagen, Denmark
WEBSITE
https://galecto.com/